SrasV1, Ncbi, Merge, bibRecord, 002525

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.

Identifieur interne : 002525 ( Ncbi/Merge ); précédent : 002524; suivant : 002526

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.

Auteurs : Adeyemi O. Adedeji [États-Unis] ; Kamalendra Singh ; Nicholas E. Calcaterra ; Marta L. Dediego ; Luis Enjuanes ; Susan Weiss ; Stefan G. Sarafianos

Source :

Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2012.

RBID : pubmed:22733076

Descripteurs français

KwdFr :
- ARN double brin (antagonistes et inhibiteurs), ARN double brin (génétique), ARN viral (antagonistes et inhibiteurs), ARN viral (génétique), Antiviraux (pharmacologie), Bibliothèques de petites molécules (pharmacologie), Cellules HEK293, Cinétique, Concentration inhibitrice 50, Conformation d'acide nucléique (), Escherichia coli (génétique), Helicase (antagonistes et inhibiteurs), Helicase (métabolisme), Humains, Protéines recombinantes (métabolisme), Protéines virales (antagonistes et inhibiteurs), Protéines virales (métabolisme), Réplication virale (), Survie cellulaire (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Transfert d'énergie par résonance de fluorescence, Triazoles (pharmacologie), Virus du SRAS (), Virus du SRAS (enzymologie), Virus du SRAS (génétique).
MESH :
- antagonistes et inhibiteurs : ARN double brin, ARN viral, Helicase, Protéines virales.
- enzymologie : Virus du SRAS.
- génétique : ARN double brin, ARN viral, Escherichia coli, Virus du SRAS.
- métabolisme : Helicase, Protéines recombinantes, Protéines virales.
- pharmacologie : Antiviraux, Bibliothèques de petites molécules, Triazoles.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Syndrome respiratoire aigu sévère.
- Cellules HEK293, Cinétique, Concentration inhibitrice 50, Conformation d'acide nucléique, Humains, Réplication virale, Survie cellulaire, Transfert d'énergie par résonance de fluorescence, Virus du SRAS.

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), Cell Survival (drug effects), DNA Helicases (antagonists & inhibitors), DNA Helicases (metabolism), Escherichia coli (genetics), Fluorescence Resonance Energy Transfer, HEK293 Cells, Humans, Inhibitory Concentration 50, Kinetics, Nucleic Acid Conformation (drug effects), RNA, Double-Stranded (antagonists & inhibitors), RNA, Double-Stranded (genetics), RNA, Viral (antagonists & inhibitors), RNA, Viral (genetics), Recombinant Proteins (metabolism), SARS Virus (drug effects), SARS Virus (enzymology), SARS Virus (genetics), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Small Molecule Libraries (pharmacology), Triazoles (pharmacology), Viral Proteins (antagonists & inhibitors), Viral Proteins (metabolism), Virus Replication (drug effects).
MESH :
- chemical , antagonists & inhibitors : DNA Helicases, RNA, Double-Stranded, RNA, Viral, Viral Proteins.
- chemical , genetics : RNA, Double-Stranded, RNA, Viral.
- chemical , metabolism : DNA Helicases, Recombinant Proteins, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Small Molecule Libraries, Triazoles.
- drug effects : Cell Survival, Nucleic Acid Conformation, SARS Virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- enzymology : SARS Virus.
- genetics : Escherichia coli, SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Fluorescence Resonance Energy Transfer, HEK293 Cells, Humans, Inhibitory Concentration 50, Kinetics.

Abstract

Severe acute respiratory syndrome (SARS) is a highly contagious disease, caused by SARS coronavirus (SARS-CoV), for which there are no approved treatments. We report the discovery of a potent inhibitor of SARS-CoV that blocks replication by inhibiting the unwinding activity of the SARS-CoV helicase (nsp13). We used a Förster resonance energy transfer (FRET)-based helicase assay to screen the Maybridge Hitfinder chemical library. We identified and validated a compound (SSYA10-001) that specifically blocks the double-stranded RNA (dsRNA) and dsDNA unwinding activities of nsp13, with 50% inhibitory concentrations (IC(50)s) of 5.70 and 5.30 μM, respectively. This compound also has inhibitory activity (50% effective concentration [EC(50)] = 8.95 μM) in a SARS-CoV replicon assay, with low cytotoxicity (50% cytotoxic concentration [CC(50)] = >250 μM), suggesting that the helicase plays a still unidentified critical role in the SARS-CoV life cycle. Enzyme kinetic studies on the mechanism of nsp13 inhibition revealed that SSYA10-001 acts as a noncompetitive inhibitor of nsp13 with respect to nucleic acid and ATP substrates. Moreover, SSYA10-001 does not affect ATP hydrolysis or nsp13 binding to the nucleic acid substrate. SSYA10-001 did not inhibit hepatitis C virus (HCV) helicase, other bacterial and viral RNA-dependent RNA polymerases, or reverse transcriptase. These results suggest that SSYA10-001 specifically blocks nsp13 through a novel mechanism and is less likely to interfere with the functions of cellular enzymes that process nucleic acids or ATP. Hence, it is possible that SSYA10-001 inhibits unwinding by nsp13 by affecting conformational changes during the course of the reaction or translocation on the nucleic acid. SSYA10-001 will be a valuable tool for studying the specific role of nsp13 in the SARS-CoV life cycle, which could be a model for other nidoviruses and also a candidate for further development as a SARS antiviral target.

DOI: 10.1128/AAC.00957-12
PubMed: 22733076

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001342
to stream PubMed, to step Curation: 001342
to stream PubMed, to step Checkpoint: 001282

Links to Exploration step

pubmed:22733076

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.</title>
<author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O" last="Adedeji">Adeyemi O. Adedeji</name>
<affiliation wicri:level="2"><nlm:affiliation>Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singh, Kamalendra" sort="Singh, Kamalendra" uniqKey="Singh K" first="Kamalendra" last="Singh">Kamalendra Singh</name>
</author>
<author><name sortKey="Calcaterra, Nicholas E" sort="Calcaterra, Nicholas E" uniqKey="Calcaterra N" first="Nicholas E" last="Calcaterra">Nicholas E. Calcaterra</name>
</author>
<author><name sortKey="Dediego, Marta L" sort="Dediego, Marta L" uniqKey="Dediego M" first="Marta L" last="Dediego">Marta L. Dediego</name>
</author>
<author><name sortKey="Enjuanes, Luis" sort="Enjuanes, Luis" uniqKey="Enjuanes L" first="Luis" last="Enjuanes">Luis Enjuanes</name>
</author>
<author><name sortKey="Weiss, Susan" sort="Weiss, Susan" uniqKey="Weiss S" first="Susan" last="Weiss">Susan Weiss</name>
</author>
<author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22733076</idno>
<idno type="pmid">22733076</idno>
<idno type="doi">10.1128/AAC.00957-12</idno>
<idno type="wicri:Area/PubMed/Corpus">001342</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001342</idno>
<idno type="wicri:Area/PubMed/Curation">001342</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001342</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001282</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001282</idno>
<idno type="wicri:Area/Ncbi/Merge">002525</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.</title>
<author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O" last="Adedeji">Adeyemi O. Adedeji</name>
<affiliation wicri:level="2"><nlm:affiliation>Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Singh, Kamalendra" sort="Singh, Kamalendra" uniqKey="Singh K" first="Kamalendra" last="Singh">Kamalendra Singh</name>
</author>
<author><name sortKey="Calcaterra, Nicholas E" sort="Calcaterra, Nicholas E" uniqKey="Calcaterra N" first="Nicholas E" last="Calcaterra">Nicholas E. Calcaterra</name>
</author>
<author><name sortKey="Dediego, Marta L" sort="Dediego, Marta L" uniqKey="Dediego M" first="Marta L" last="Dediego">Marta L. Dediego</name>
</author>
<author><name sortKey="Enjuanes, Luis" sort="Enjuanes, Luis" uniqKey="Enjuanes L" first="Luis" last="Enjuanes">Luis Enjuanes</name>
</author>
<author><name sortKey="Weiss, Susan" sort="Weiss, Susan" uniqKey="Weiss S" first="Susan" last="Weiss">Susan Weiss</name>
</author>
<author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Cell Survival (drug effects)</term>
<term>DNA Helicases (antagonists & inhibitors)</term>
<term>DNA Helicases (metabolism)</term>
<term>Escherichia coli (genetics)</term>
<term>Fluorescence Resonance Energy Transfer</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Kinetics</term>
<term>Nucleic Acid Conformation (drug effects)</term>
<term>RNA, Double-Stranded (antagonists & inhibitors)</term>
<term>RNA, Double-Stranded (genetics)</term>
<term>RNA, Viral (antagonists & inhibitors)</term>
<term>RNA, Viral (genetics)</term>
<term>Recombinant Proteins (metabolism)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (enzymology)</term>
<term>SARS Virus (genetics)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Small Molecule Libraries (pharmacology)</term>
<term>Triazoles (pharmacology)</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (metabolism)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN double brin (antagonistes et inhibiteurs)</term>
<term>ARN double brin (génétique)</term>
<term>ARN viral (antagonistes et inhibiteurs)</term>
<term>ARN viral (génétique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Bibliothèques de petites molécules (pharmacologie)</term>
<term>Cellules HEK293</term>
<term>Cinétique</term>
<term>Concentration inhibitrice 50</term>
<term>Conformation d'acide nucléique ()</term>
<term>Escherichia coli (génétique)</term>
<term>Helicase (antagonistes et inhibiteurs)</term>
<term>Helicase (métabolisme)</term>
<term>Humains</term>
<term>Protéines recombinantes (métabolisme)</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Protéines virales (métabolisme)</term>
<term>Réplication virale ()</term>
<term>Survie cellulaire ()</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Transfert d'énergie par résonance de fluorescence</term>
<term>Triazoles (pharmacologie)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (enzymologie)</term>
<term>Virus du SRAS (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Helicases</term>
<term>RNA, Double-Stranded</term>
<term>RNA, Viral</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Double-Stranded</term>
<term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA Helicases</term>
<term>Recombinant Proteins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Small Molecule Libraries</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>ARN double brin</term>
<term>ARN viral</term>
<term>Helicase</term>
<term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term>
<term>Nucleic Acid Conformation</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Escherichia coli</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN double brin</term>
<term>ARN viral</term>
<term>Escherichia coli</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Helicase</term>
<term>Protéines recombinantes</term>
<term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Bibliothèques de petites molécules</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Fluorescence Resonance Energy Transfer</term>
<term>HEK293 Cells</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Kinetics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Cellules HEK293</term>
<term>Cinétique</term>
<term>Concentration inhibitrice 50</term>
<term>Conformation d'acide nucléique</term>
<term>Humains</term>
<term>Réplication virale</term>
<term>Survie cellulaire</term>
<term>Transfert d'énergie par résonance de fluorescence</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a highly contagious disease, caused by SARS coronavirus (SARS-CoV), for which there are no approved treatments. We report the discovery of a potent inhibitor of SARS-CoV that blocks replication by inhibiting the unwinding activity of the SARS-CoV helicase (nsp13). We used a Förster resonance energy transfer (FRET)-based helicase assay to screen the Maybridge Hitfinder chemical library. We identified and validated a compound (SSYA10-001) that specifically blocks the double-stranded RNA (dsRNA) and dsDNA unwinding activities of nsp13, with 50% inhibitory concentrations (IC(50)s) of 5.70 and 5.30 μM, respectively. This compound also has inhibitory activity (50% effective concentration [EC(50)] = 8.95 μM) in a SARS-CoV replicon assay, with low cytotoxicity (50% cytotoxic concentration [CC(50)] = >250 μM), suggesting that the helicase plays a still unidentified critical role in the SARS-CoV life cycle. Enzyme kinetic studies on the mechanism of nsp13 inhibition revealed that SSYA10-001 acts as a noncompetitive inhibitor of nsp13 with respect to nucleic acid and ATP substrates. Moreover, SSYA10-001 does not affect ATP hydrolysis or nsp13 binding to the nucleic acid substrate. SSYA10-001 did not inhibit hepatitis C virus (HCV) helicase, other bacterial and viral RNA-dependent RNA polymerases, or reverse transcriptase. These results suggest that SSYA10-001 specifically blocks nsp13 through a novel mechanism and is less likely to interfere with the functions of cellular enzymes that process nucleic acids or ATP. Hence, it is possible that SSYA10-001 inhibits unwinding by nsp13 by affecting conformational changes during the course of the reaction or translocation on the nucleic acid. SSYA10-001 will be a valuable tool for studying the specific role of nsp13 in the SARS-CoV life cycle, which could be a model for other nidoviruses and also a candidate for further development as a SARS antiviral target.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22733076</PMID>
<DateCompleted><Year>2013</Year>
<Month>01</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>56</Volume>
<Issue>9</Issue>
<PubDate><Year>2012</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.</ArticleTitle>
<Pagination><MedlinePgn>4718-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00957-12</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a highly contagious disease, caused by SARS coronavirus (SARS-CoV), for which there are no approved treatments. We report the discovery of a potent inhibitor of SARS-CoV that blocks replication by inhibiting the unwinding activity of the SARS-CoV helicase (nsp13). We used a Förster resonance energy transfer (FRET)-based helicase assay to screen the Maybridge Hitfinder chemical library. We identified and validated a compound (SSYA10-001) that specifically blocks the double-stranded RNA (dsRNA) and dsDNA unwinding activities of nsp13, with 50% inhibitory concentrations (IC(50)s) of 5.70 and 5.30 μM, respectively. This compound also has inhibitory activity (50% effective concentration [EC(50)] = 8.95 μM) in a SARS-CoV replicon assay, with low cytotoxicity (50% cytotoxic concentration [CC(50)] = >250 μM), suggesting that the helicase plays a still unidentified critical role in the SARS-CoV life cycle. Enzyme kinetic studies on the mechanism of nsp13 inhibition revealed that SSYA10-001 acts as a noncompetitive inhibitor of nsp13 with respect to nucleic acid and ATP substrates. Moreover, SSYA10-001 does not affect ATP hydrolysis or nsp13 binding to the nucleic acid substrate. SSYA10-001 did not inhibit hepatitis C virus (HCV) helicase, other bacterial and viral RNA-dependent RNA polymerases, or reverse transcriptase. These results suggest that SSYA10-001 specifically blocks nsp13 through a novel mechanism and is less likely to interfere with the functions of cellular enzymes that process nucleic acids or ATP. Hence, it is possible that SSYA10-001 inhibits unwinding by nsp13 by affecting conformational changes during the course of the reaction or translocation on the nucleic acid. SSYA10-001 will be a valuable tool for studying the specific role of nsp13 in the SARS-CoV life cycle, which could be a model for other nidoviruses and also a candidate for further development as a SARS antiviral target.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adedeji</LastName>
<ForeName>Adeyemi O</ForeName>
<Initials>AO</Initials>
<AffiliationInfo><Affiliation>Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Kamalendra</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Calcaterra</LastName>
<ForeName>Nicholas E</ForeName>
<Initials>NE</Initials>
</Author>
<Author ValidYN="Y"><LastName>DeDiego</LastName>
<ForeName>Marta L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y"><LastName>Enjuanes</LastName>
<ForeName>Luis</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weiss</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sarafianos</LastName>
<ForeName>Stefan G</ForeName>
<Initials>SG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI074389</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R33 AI079801</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI079801</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI094715</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI074389</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI079801</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI076119</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI094715</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI076119</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000601132">SSYA10-001</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber>
<NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>6</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22733076</ArticleId>
<ArticleId IdType="pii">AAC.00957-12</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.00957-12</ArticleId>
<ArticleId IdType="pmc">PMC3421890</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Mol Biol. 2002 Nov 29;324(3):409-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12445778</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2006 Jul 7;281(27):18265-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16670085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Struct Mol Biol. 2009 Feb;16(2):212-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19151724</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 1990;59:289-329</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2165383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2005 Oct;4(10):845-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16184083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 1996 Oct 15;319 ( Pt 2):619-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8912703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gene. 2006 Feb 15;367:17-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16337753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem Anticancer Agents. 2005 May;5(3):183-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15992349</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1993 Feb 5;268(4):2269-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8381400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Jun;74(11):5213-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10799597</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2009 Jan;44(1):117-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18455273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Herpes. 2003 Aug;10(2):46-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14577954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Nov;80(21):10900-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16928748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2002 Sep;55(3):397-412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12206878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Screen. 1999;4(2):67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2003 Oct 10;278(41):39578-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Microbiol. 2005 Sep;57(6):1664-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16135232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2003 Mar 28;278(13):11289-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12522214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2002 Apr;8(4):392-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11927946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2007 Nov 1;15(21):6775-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17761423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2009 Mar 15;19(6):1636-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Virol J. 2011;5:80-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21769307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jun 18;279(25):26005-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15087464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2595-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1704818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Struct Mol Biol. 2006 Mar;13(3):242-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16474403</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Farmaco. 2004 Nov;59(11):893-901</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15544794</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(5):e36521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22615777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jan;79(2):696-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15613297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Apr 6;282(14):10594-604</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17259182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2008 Dec;43(12):2688-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18395299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2005 Jan 12;24(1):180-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15565170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2008 May;4(5):e1000054</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18451981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1991 Mar;181(1):22-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1825251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2004 Oct 8;343(1):101-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15381423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2001 Jan 5;291(5501):121-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11141562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Nov;74(21):9878-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11024114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Breast Cancer Res. 2012;14(2):R52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22429491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2009;154(3):507-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19224332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1997 Jan 17;275(5298):377-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8994032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2004 Oct 25;328(2):208-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15464841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 16;279(3):1637-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14561748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2009 Dec;68(6):906-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20002085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 Apr;81(Pt 4):853-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10725411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2007;2(5):e459</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17520018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2002 Apr;8(4):386-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11927945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Commun (Camb). 2007 Nov 14;(42):4413-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17957304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Farmaco. 2004 Apr;59(4):279-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081345</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2005 Mar;12(3):303-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15797214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Microbiol. 1992 Jan;6(1):5-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1310794</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 1981;50:233-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6267987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5619-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2011 Nov;46(11):5698-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21925774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2010 Mar;54(3):977-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20028820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 May 15;423(6937):309-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(12):e15049</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21203539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2007 Aug 22;26(16):3804-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17641684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1999 Nov 5;274(45):31839-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10542208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1997 Dec 19;272(51):32267-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9405431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Dec 3;462(7273):581-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19956250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carbohydr Res. 2006 Sep 25;341(13):2187-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16839524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2012 Jan;40(1):345-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21908397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 2000;69:651-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10966472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2006;66:193-292</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16877062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 1996;65:169-214</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8811178</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
</region>
</list>
<tree><noCountry><name sortKey="Calcaterra, Nicholas E" sort="Calcaterra, Nicholas E" uniqKey="Calcaterra N" first="Nicholas E" last="Calcaterra">Nicholas E. Calcaterra</name>
<name sortKey="Dediego, Marta L" sort="Dediego, Marta L" uniqKey="Dediego M" first="Marta L" last="Dediego">Marta L. Dediego</name>
<name sortKey="Enjuanes, Luis" sort="Enjuanes, Luis" uniqKey="Enjuanes L" first="Luis" last="Enjuanes">Luis Enjuanes</name>
<name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
<name sortKey="Singh, Kamalendra" sort="Singh, Kamalendra" uniqKey="Singh K" first="Kamalendra" last="Singh">Kamalendra Singh</name>
<name sortKey="Weiss, Susan" sort="Weiss, Susan" uniqKey="Weiss S" first="Susan" last="Weiss">Susan Weiss</name>
</noCountry>
<country name="États-Unis"><region name="Missouri (État)"><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O" last="Adedeji">Adeyemi O. Adedeji</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002525 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002525 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:22733076
   |texte=   Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:22733076" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki